Abstract
Autoimmune liver diseases are a panel of chronic inflammatory diseases caused by abnormal immune attack against hepatocytes or bile duct epithelial cell, including autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), IgG4-related sclerosing cholangitis (IgG4-SC), and overlap syndrome. Currently main drug treatments of autoimmune liver diseases contain corticosteroids, immunosuppressant and other immune-modulation therapy. Using anti-CD20 to deplete B cells has achieved biochemical improvement in patients with IgG4-SC or PBC. There are several clinical trials focus on immune cell transfusion and novel target drug therapy finished or being conducted.